Previous 10 | Next 10 |
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Outcomes from clinical trial results can propel a biotech's stock price positively or negatively, regardless of the size of the company. Currently, biotech investors are eagerly awaiting data from AnaptysBio (NASDAQ: ANAB) , which has a $435 million market cap, on a drug that recently fe...
– Conference Call and Webcast to Follow at 5:00 p.m. EDT / 2:00 p.m. PDT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2020 financial results will be released on Tuesday, May 5, 2020 after the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, E...
Bristol Myers Squibb (NYSE: BMY) started off the week by delivering a double-dose of good news regarding its cancer drug Opdivo: In two late-stage clinical trials testing the drug in patients with kidney cancer and mesothelioma, it met its primary endpoints. In the CheckMate-9ER clinical tr...
Gainers: Cyclacel Pharmaceuticals (NASDAQ: CYCC ) +91% . More news on: Cyclacel Pharmaceuticals, Inc., Benitec Biopharma Limited, VBI Vaccines Inc., Stocks on the move, , Read more ...
Shares of Exelixis (NASDAQ: EXEL) were skyrocketing 25.5% as of 11:12 a.m. EDT on Monday. The big jump came after Exelixis and Bristol Myers Squibb (NYSE: BMY) announced positive top-line results from a late-stage clinical study evaluating a combination of Opdivo and Cabometyx in previou...
Bristol-Myers Squibb (NYSE: BMY ) and Exelixis (NASDAQ: EXEL ) announce positive results from a Phase 3 clinical trial, CheckMate-9ER , evaluating the combination of Opdivo (nivolumab) and Cabometyx (cabozantinib) for the first-line treatment of advanced/metastatic renal cell carcinoma (R...
Study met primary endpoint of significantly improving progression-free survival, and secondary endpoints of overall survival and objective response rate vs. sunitinib Opdivo in combination with CABOMETYX demonstrates clinically meaningful efficacy results across all endpoints and pr...
For the past two months, investors have been taken on a wild ride due to the proliferation of coronavirus disease 2019 (COVID-19) in the U.S. and around the world. After hitting an all-time closing high on Feb. 19, it took the benchmark S&P 500 just 17 trading sessions to fall into bear m...
The treatment landscape for kidney cancer has undergone a significant shift in the last decade. Between 2006 and 2009, the U.S. Food and Drug Administration (FDA) approved six drugs for renal cell carcinoma (RCC), the most common form of kidney cancer. A new slate of targeted therapies and immun...
News, Short Squeeze, Breakout and More Instantly...
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2024 financial results will be released on Tuesday, August 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Ex...
2024-07-11 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...